Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Illumina Inc Market Cap
From what 15 stock analysts predict, the share price for Illumina Inc (ILMN) might increase by 10.39% in the next year. This is based on a 12-month average estimation for ILMN. Price targets go from $85.00 to $258.00. The majority of stock analysts believe ILMN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
ILMN is a stock in Health Care which has been forecasted to be worth $154.60 as an average. On the higher end, the forecast price is $258.00 USD by conor mcnamara from RBC Capital and on the lower end ILMN is forecasted to be $85.00 by luke sergott from Barclays.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| mason carrico Stephens | Buy | $170.0 | maintained | Feb 14, 2024 |
| daniel arias Stifel Nicolaus | Buy | $160.0 | maintained | Feb 13, 2024 |
| luke sergott Barclays | Sell | $85.0 | rated | Feb 9, 2024 |
| patrick b donnelly Citi | Hold | $145.0 | reiterated | Feb 9, 2024 |
| david westenberg Piper Sandler | Buy | $190.0 | initiatedcoverage | Feb 9, 2024 |
| puneet souda Leerink Partners | Buy | $170.0 | maintained | Feb 9, 2024 |
| daniel brennan TD Cowen | Hold | $150.0 | maintained | Feb 8, 2024 |
| conor mcnamara RBC Capital | Buy | $258.0 | reiterated | Feb 8, 2024 |
| michael ryskin Bank of America Securities | Sell | $105.0 | reiterated | Feb 8, 2024 |
| catherine ramsey schulte Robert W. Baird | Hold | $144.0 | maintained | Jan 29, 2024 |
| kyle mikson cfa Canaccord Genuity | Hold | $130.0 | maintained | Jan 16, 2024 |
| shubhangi gupta HSBC | Hold | $150.0 | downgraded | Jan 15, 2024 |
| sung ji nam Scotiabank | Buy | $185.0 | upgraded | Dec 19, 2023 |
| eve burstein Bernstein | Hold | $127.0 | upgraded | Dec 15, 2023 |
| doug schenkel Wolfe Research | Buy | $175.0 | initiatedcoverage | Dec 12, 2023 |
| vijay kumar Evercore ISI | Buy | $160.0 | maintained | Nov 10, 2023 |
| john sourbeer UBS | Hold | $111.0 | maintained | Nov 10, 2023 |
| rachel vatnsdal J.P. Morgan | Hold | $110.0 | maintained | Nov 10, 2023 |
| dan leonard Credit Suisse | Hold | $200.0 | rated | Aug 9, 2023 |
| tejas savant Morgan Stanley | Hold | $225.0 | maintained | Apr 26, 2023 |
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
When did it IPO
2000
Staff Count
10,590
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Jacob Thaysen Ph.D.
Market Cap
$22.79B
In 2023, ILMN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ILMN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
EBAY-USD
$43.8
FITB-USD
$33.49
ALGN-USD
$316.56
$199.73
$1523.19
PTC-USD
$178.19
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
